Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Publication date: Mar 12, 2019

Background: Pathologic changes in cortical gray matter (GM) and leptomeninges contribute to disability worsening in patients with multiple sclerosis (MS), but there is little evidence whether disease-modifying treatments can slow down cortical pathology in MS. Objectives: To investigate the effect of teriflunomide (TFM) and dimethyl fumarate (DMF) in reducing cortical pathology, as determined by percentage cortical volume change (PCVC) and leptomeningeal contrast enhancement (LMCE) on MRI. Methods: This was a retrospective, single-center, observational study that selected 60 TFM- and 60 DMF-treated MS patients over 24 months. Results: TFM had a lower rate of PCVC compared to DMF over 24 months (-0.2% vs. -2.94%, p = 0.004). Similar results were observed for percentage GM volume change over 0⁻12 (p = 0.044) and 0⁻24 (-0.44% vs. -3.12%, p = 0.015) months. No significant differences were found between the TFM and DMF groups in the frequency and number of LMCE foci over the follow-up. TFM showed a numerically lower rate of whole brain atrophy over 24 months (p = 0.077), compared to DMF. No significant clinical or MRI lesion differences between TFM and DMF were detected over follow-up. Conclusions: These findings suggest that TFM has a superior effect on the preservation of cortical GM volume, compared to DMF.

Zivadinov, R., Bergsland, N., Carl, E., Ramasamy, D.P., Hagemeier, J., Dwyer, M.G., Lizarraga, A.A., Kolb, C., Hojnacki, D., and Weinstock-Guttman, B. Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. 17529. 2019 J Clin Med (8):3.

Concepts Keywords
Atrophy MRI
Brain DMF
Cortical Teriflunomide
Dimethyl Multiple sclerosis
Disability Fluid-attenuated inversion recovery
DMF Cerebral atrophy
Foci Fungicides
Frequency Fumarates
Gray Matter Organic chemistry
Inflammation Dimethyl fumarate
Leptomeningeal Organic compounds
Leptomeninges Chemistry
Lesion
MRI
Multiple Sclerosis
Pathology
TFM

Semantics

Type Source Name
gene UNIPROT CYREN
gene UNIPROT AR
gene UNIPROT EGR3
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
disease MESH Inflammation
disease MESH Atrophy
drug DRUGBANK Dimethyl fumarate
drug DRUGBANK Teriflunomide

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *